High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis

Puoti M, Foster GR, Wang S, et al. High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis. J Hepatol. 2018;69(2):293-300.

Publication Type:

Journal Article

Authors:

Puoti, M.; Foster, G.R.; Wang, S; et, al

Source:

J Hepatol, Volume 69, Issue 2, p.293-300 (2018)

Cited On:

Export Citation:
RIS Format
Top